Press release
Geron Corporation Reports Third Quarter 2022 Financial Results and Upcoming Expected Milestones
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023 Current and Projected Financial Resources Expected
About this update from Geron Corporation
[{"type":"text","content":"\nTop-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Continue to be Expected in Early January 2023\n\nCurrent and Projected Financial Resources Expected to Support Planned Milestones and Operations Through Middle of 2024\n\nConference Call Scheduled for 9:00 a.m. ET Today\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported financial results for the third quarter of 2022 and upcoming expected milestones.\n\n“Throughout the year, we have highlighted our vision for Geron to become a leader in the treatment of hematologic malignancies through the expected development and commercialization of imetelstat. We continue to believe that the differentiating qualities of imetelstat, including potential for disease modification and durability of effect, could transform the treatment landscape for lower risk myelodysplastic syndromes and JAK inhibitor relapsed/refractory myelofibrosis,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “We’re looking forward to the IMerge Phase 3 top-line results expected in just two months that if positive, will advance the company from late-stage development to commercialization and provide meaningful value for stockholders and patients.”\n\nUpcoming Expected Milestones\n\n2022\n\n\nPhase 2 and non-clinical updates expected at upcoming medical meeting\n\n\nOpen remaining selected clinical sites in Phase 3 IMpactMF trial evaluating imetelstat vs. best available therapy in patients with JAK inhibitor relapsed/refractory myelofibrosis\n\n\nStart Phase 2 IMpress investigator-led study of single-agent imetelstat in relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk MDS\n\n\n2023\n\n\nTop-line results from IMerge Phase 3 in lower risk myelodysplastic syndromes (MDS) in early January\n\n\nNew Drug Application submission in lower risk MDS in the U.S. in the first half of the year\n\n\nMarketing Authorization Application submission in lower risk MDS in the EU in the second half of the year\n\n\nPreliminary data from IMproveMF Phase 1 study of imetelstat in combination with ruxolitinib in frontline myelofibrosis by year-end\n\n\n2024\n\n\nU.S. approval and commercial launch in low...